Salona Global Medical Device Corporation

Thank you for joining us today. I'd like to introduce Solana Global Medical Device Corporation's Vice President of Capital Markets and Financial Communications, Jethro Roth-Kuschel.

Thank you, Chloe, and welcome to the second quarter earnings call for Solana Global Medical Device Corporation, listed on the TSX-V under the ticker SGMD. I'd like to remind everyone that today's discussion will include forward-looking information and forward-looking statements, future-oriented financial information, and non-IFRS measures regarding future events and our future financial performance. These statements reflect our views as of today only and should not be considered as representing our views for any subsequent date and, except as required by law, We do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after today, many of which are beyond our control. These statements are also subject to material risks and uncertainties that could cause actual results to differ materially from expectations reflected in the forward-looking statements. A discussion of these risk factors is fully discussed or referenced to in Solana Global's disclosure documents filed on EDGAR and CDAR. Unless otherwise specified, all dollar amounts in this call are expressed in Canadian dollars. During this call, we may also refer to certain non-GAAP financial measures. For information regarding our non-GAAP financials and a reconciliation of GAAP to non-GAAP measures, please also refer to our EDGAR and CDAR filings. Ladies and gentlemen, allow me to introduce Solana Global Medical Device Corporation's CEO, Luke Ballstick. Luke.

Thank you, Jethro. First, I would like to welcome the Daymar Plastics team into the Solana Global family. We announced the closure of this acquisition on September 23, 2022. We are very excited to have them on our team and look forward to including them in our future quarterly results. Today we posted our reviewed second fiscal quarter financials ending August 31st, 2022. This was a strong quarter, and I want to jump right to the highlights before handing it over to Les Cross, our executive chairman, to describe our market, our business model, and our team. This was our first full quarter we can use as a year-over-year comparison. We generated 153% year-over-year growth in revenues, with a 300% year-over-year increase in total cash receipts for the second quarter, taking in approximately $13.6 million, including $4.2 million from the US $7.5 million sales order. We built a record order book backlog to over $18.5 million during the quarter, as a result of increasing our focus on organic sales. We generated 152% year-over-year gross margin growth and $1,427,000 in positive adjusted EBITDA for the six months ended August 31st, 2022. We continue to build a strong pipeline of cash flow positive acquisition targets for future acquisitions in the coming quarters. We are now negotiating acquisition agreements, including a contract manufacturing agreement and transition services agreement for a 26 million annual revenue potential acquisition. It's LOI announced August 15th of 2022. We are pursuing an optimized debt structure for closing. All in all, a very busy and successful quarter both in terms of generating cash and building a platform for the future. I'll now turn the call over to Les Cross, Celana Global Medical Device Corporation's Executive Chairman. Les?